Shanghai - Delayed Quote CNY

PIENTZEHUANG (600436.SS)

207.55
+0.42
+(0.20%)
At close: May 9 at 3:00:03 PM GMT+8
Loading Chart for 600436.SS
  • Previous Close 207.13
  • Open 207.00
  • Bid 207.55 x --
  • Ask 207.56 x --
  • Day's Range 206.71 - 208.43
  • 52 Week Range 189.90 - 284.34
  • Volume 1,297,791
  • Avg. Volume 2,238,301
  • Market Cap (intraday) 125.218B
  • Beta (5Y Monthly) 0.98
  • PE Ratio (TTM) 41.84
  • EPS (TTM) 4.96
  • Earnings Date Apr 30, 2025
  • Forward Dividend & Yield 3.47 (1.67%)
  • Ex-Dividend Date Oct 22, 2024
  • 1y Target Est --

Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally. Its products include Chinese herbal decoction pieces, health foods, beverages, medical equipment, tonics, Chinese herbal medicine slices, cosmetics, and daily chemical products. The company was founded in 1956 and is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical., Ltd is a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.

www.zzpzh.com.cn

2,839

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600436.SS

View More

Performance Overview: 600436.SS

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600436.SS
3.24%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

600436.SS
11.90%
SSE Composite Index (000001.SS)
5.95%

3-Year Return

600436.SS
28.73%
SSE Composite Index (000001.SS)
11.25%

5-Year Return

600436.SS
47.46%
SSE Composite Index (000001.SS)
15.43%

Compare To: 600436.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600436.SS

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    125.22B

  • Enterprise Value

    124.91B

  • Trailing P/E

    41.76

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.65

  • Price/Book (mrq)

    8.20

  • Enterprise Value/Revenue

    11.61

  • Enterprise Value/EBITDA

    34.83

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.91%

  • Return on Assets (ttm)

    11.65%

  • Return on Equity (ttm)

    19.58%

  • Revenue (ttm)

    10.76B

  • Net Income Avi to Common (ttm)

    3B

  • Diluted EPS (ttm)

    4.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.39B

  • Total Debt/Equity (mrq)

    6.84%

  • Levered Free Cash Flow (ttm)

    3.71B

Research Analysis: 600436.SS

View More

Company Insights: 600436.SS

Research Reports: 600436.SS

View More

People Also Watch